9 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Advanced small bowel adenocarcinoma is cancer of the small intestine that has spread to the liver, peritoneum or elsewhere, treated with the chemotherapy used for bowel cancer, oxaliplatin with a fluoropyrimidine, then taxanes or irinotecan. The exception is the sizeable minority with mismatch-repair-deficient tumours, for whom the immunotherapy pembrolizumab is an approved option.
Metastatic small bowel adenocarcinoma has been treated for two decades with regimens borrowed from colorectal cancer, guided by phase 2 trials rather than randomised evidence. Capecitabine with oxaliplatin (CAPOX) produced responses in about half of patients in a phase 2 trial at MD Anderson (Journal of Clinical Oncology 2009) and, with FOLFOX, became the first-line standard; FOLFIRI is used in second line, and two small single-arm phase 2 trials of FOLFOX, with response rates of 45 and 48.5 percent, and retrospective series supported these choices. Bevacizumab is added by analogy with colon cancer, while anti-EGFR antibodies are not used because a phase 2 trial of panitumumab in RAS wild-type tumours showed no meaningful activity. The NCCN guideline lists taxane-based regimens as a further option, in second line in its 2019 version; the current version sits behind a login and could not be re-read on 18 November 2026.
The molecular exceptions matter more than in colon cancer. Mismatch repair deficiency, found in a larger proportion of small bowel than colorectal adenocarcinomas, predicts benefit from pembrolizumab, given accelerated approval in the United States in May 2017 for previously treated mismatch-repair-deficient solid tumours and recommended by the NCCN guideline for these patients; the ZEBRA phase 2 trial of pembrolizumab in 40 previously treated patients with unselected small bowel adenocarcinoma missed its response target (3 confirmed responses, 8 percent), while half of the patients with microsatellite-unstable tumours responded. HER2 amplification or mutation occurs in a subset and responds to trastuzumab-based therapy or trastuzumab deruxtecan in tumour-agnostic trials, and comprehensive genomic profiling is recommended for every patient with advanced disease. Resection of limited liver or peritoneal metastases and cytoreductive surgery with HIPEC are considered in selected patients, and circulating tumour DNA is being explored for monitoring. Survival remains shorter than in colorectal cancer, in part because the tumours respond less and in part because they are diagnosed late.
| Setting | Approach | Guideline |
|---|---|---|
| First line, mismatch-repair proficient | CAPOX or FOLFOX, with bevacizumab considered; taxane-based regimens as an alternative. | not mapped |
| First line, mismatch-repair deficient | Pembrolizumab (tumour-agnostic approval); nivolumab with ipilimumab as an alternative. | not mapped |
| Second line | FOLFIRI or a taxane; pembrolizumab if mismatch-repair deficient and not yet given; trastuzumab-based therapy or trastuzumab deruxtecan for HER2-positive tumours. | not mapped |
| Limited metastases | Resection of liver metastases or cytoreductive surgery with HIPEC for limited peritoneal disease in selected patients. | not mapped |
| All patients | Comprehensive genomic profiling to find HER2, mismatch repair deficiency and rare actionable alterations; referral to trials. | not mapped |